Why a Heart Recipient's Drug Cost Jumped From $180 to $1,000

Payton Herres, 26, has depended on a donor heart since childhood and takes Everolimus to prevent her body from rejecting the organ. Her insurer initially refused to cover the drug, then reversed itself after her story spread on social media, but the approval came with a sharp rise in cost-sharing: from about $180 to roughly $1,000 for a 90-day supply. Herres called the outcome a 'ghost approval' — coverage that exists on paper but does not make the treatment financially accessible.

The case reached billionaire investor Mark Cuban after Mary Cutter, the mother of the organ donor, offered to pay for the medicine. Cutter's son Christian died in 2012 and his heart went to Herres. When Cutter learned about the insurance dispute, she said she would do whatever she could to keep 'her heart and my son's heart' beating.

Cuban publicly criticized the insurer and his Mark Cuban Cost Plus Drug Company supplied the drug for about $300 for a 90-day course, according to Yahoo Finance. That is far below the amount Herres would have paid through insurance after the partial reapproval. The episode is a specific case of a broader issue in US healthcare: an authorization can be granted while the patient's out-of-pocket cost remains unaffordable.

What the Everolimus Dispute Exposes About Off-Label Coverage and Drug Prices

Why Insurers Treat Everolimus Differently for Heart Recipients

Everolimus, sold under names including Zortress, is FDA-approved to prevent rejection after kidney and liver transplants. For heart transplantation, it is prescribed off-label, and the FDA's prescribing information for Zortress warns against use in heart transplant patients. Off-label use is not illegal or automatically bad medicine: physicians may prescribe a drug for an indication the regulator has not approved. But payers often use the absence of an FDA indication to deny or limit coverage. In Herres's case, her transplant team considered the drug medically necessary for her, yet the insurer's initial denial and later high cost-sharing show how the off-label label can become a financial barrier rather than a clinical one.

How Mark Cuban's Cost Plus Model Changed the Price

Mark Cuban Cost Plus Drug Company sells medicines through a direct-to-consumer online pharmacy, often at a set markup over acquisition cost. For this everolimus supply, the reported cash price was about $300 for 90 days, compared with roughly $1,000 through Herres's insurance after the partial approval. That price gap does not necessarily mean the insurer paid $1,000 for the same product; insured patients' cost-sharing can be driven by deductibles, formulary tiers and pharmacy benefit manager contracts. But the case illustrates why a cash price from a discount pharmacy may be lower than the patient's insured out-of-pocket cost, particularly for off-label or non-formulary drugs.

The Role of Public Pressure and the Donor Family

The insurer moved only after Herres made her story public and it gained attention; the donor mother's offer added emotional weight. Mark Cuban's involvement then turned a patient hardship into a visible criticism of the existing pharmacy payment system. The sequence matters because it shows that in the US system, individual coverage decisions can be reversed by reputation and social media pressure rather than purely by clinical or financial logic. That can produce relief for one patient, but it does not create a reliable rule for the next patient in the same situation.

What Transplant Patients and Plan Sponsors Can Do After the Herres Case

For patients and families facing similar off-label transplant drug costs, the Herres case points to several practical steps:

  • Ask the transplant team to document the off-label use as medically necessary for the individual patient and to support any insurer appeal with that history, because Herres's insurer only reversed its denial after the case became public.
  • Do not treat an approval letter as proof of affordability. After coverage was reinstated, Herres's 90-day cost rose to about $1,000, which she called a 'ghost approval' — verify the actual out-of-pocket amount before filling the prescription.
  • Compare the insured price with a direct cash price. Mark Cuban Cost Plus Drug Company supplied the same 90-day course for roughly $300, showing that the lowest-cost option may sit outside the insurance benefit.
  • If you manage a health plan, check whether off-label transplant maintenance drugs are placed on a high cost-sharing tier; the Herres case shows that such decisions can become public and force reversal.

Risk & Opportunity Assessment

Commercial RiskMediumThe unnamed insurer faces member dissatisfaction and potential customer loss because its initial denial and later $1,000 cost-sharing for a transplant maintenance drug triggered public criticism and intervention by Mark Cuban's pharmacy.
Competitive RiskHighMark Cuban Cost Plus Drug Company offered the 90-day supply for about $300 versus roughly $1,000 through insurance, exposing the insured pharmacy channel's price disadvantage for off-label drugs.
Regulatory RiskMediumEverolimus is off-label for heart transplant and the FDA warns against its use in that setting, so payers and prescribers could face closer scrutiny or coverage-policy pressure around off-label transplant drug approvals.
Reputation RiskHighThe insurer was publicly criticized by Mark Cuban, and donor mother Mary Cutter offered to pay, amplifying a 'ghost approval' narrative that can damage payer brand trust.
Technology DisruptionMediumCost Plus Drug Company's online direct-to-consumer model bypasses traditional pharmacy benefit manager pricing for a specialty off-label drug, a structural challenge to the insured pharmacy supply chain.
Commercial OpportunityHighThe case gives Mark Cuban Cost Plus Drug Company a high-visibility example of undercutting insurance pricing for an off-label transplant drug, potentially attracting patients with expensive maintenance prescriptions.